Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
| Website: | www.bms.com |
| Email: | timothy.power@bms.com |
| Main Phone: | +1 212 546-4000 |
| Address: | 430 East 29th Street |
| Address 2: | 14th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | US |
| Postal Code: | 10016 |
| Exchange: | NYE |
| CEO: | Giovanni Caforio |
| Employees: | 30000 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Nearly all the increases were below 10%, and the median hike was 4.8%, down slightly from the previous year.
Berkshire disclosed $5.7 billion of new healthcare stakes, including more than $1.8 billion each in Abbvie, Bristol-Myers Squibb and Merck and $136 million in Pfizer.
An NDA for MyoKardia's lead candidate — mavacamten for obstructive hypertrophic cardiomyopathy — is expected to be submitted to the FDA in Q1 2021.
90% of all prescriptions involve generics, medications that no longer hold patent protetection.
Bloomberg News reported the contact and that Gilead did not express interest in a merger.
The company reported an 11% increase in revenue and 17% increase in adjusted profit, while maintaining its full-year forecast.
Sometimes some things work, and sometimes other things work...
The U.S.-China trade disagreement, several Fed rate hikes, global politics and volatile oil prices have created a whirlwind of turbulence.
Here's why McKesson stock is not just cheap — it’s incredibly cheap.
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
| Website: | www.bms.com |
| Email: | timothy.power@bms.com |
| Main Phone: | +1 212 546-4000 |
| Address: | 430 East 29th Street |
| Address 2: | 14th Floor |
| State: | NY |
| City / Town: | New York |
| Country: | US |
| Postal Code: | 10016 |
| Exchange: | NYE |
| CEO: | Giovanni Caforio |
| Employees: | 30000 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Nearly all the increases were below 10%, and the median hike was 4.8%, down slightly from the previous year.
Berkshire disclosed $5.7 billion of new healthcare stakes, including more than $1.8 billion each in Abbvie, Bristol-Myers Squibb and Merck and $136 million in Pfizer.
An NDA for MyoKardia's lead candidate — mavacamten for obstructive hypertrophic cardiomyopathy — is expected to be submitted to the FDA in Q1 2021.
90% of all prescriptions involve generics, medications that no longer hold patent protetection.
Bloomberg News reported the contact and that Gilead did not express interest in a merger.
The company reported an 11% increase in revenue and 17% increase in adjusted profit, while maintaining its full-year forecast.
Sometimes some things work, and sometimes other things work...
The U.S.-China trade disagreement, several Fed rate hikes, global politics and volatile oil prices have created a whirlwind of turbulence.
Here's why McKesson stock is not just cheap — it’s incredibly cheap.
| Last Price 66.54 | Change $ 0.52 | Change % 0.79 | Tick N/A |
| Bid 66.40 | Bid Size 100.00 | Ask 66.60 | Ask Size 200.00 |
| Open 66.02 | High 66.86 | Low 65.54 | Prev Close 66.02 |
| Last Trade | Volume 11.3 mi | 52 Wk Hi 68.34 | 52 Wk Low 45.76 |
| Market Cap 150.4 bi | Ex-Div Date | Div Rate 1.96 | Yield 2.9460 |
| Shares 2,259,751,518.00 | EPS (TTM) -0.30 | PE Ratio -220.10 | Exchange NYSE |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 9 | 156 |
| Number of Buys | 5 | 95 |
| Number of Sells | 4 | 61 |
| Net Activity | 14249 | 331983 |
| Last 10 Buys | Shares |
|---|---|
| Dinesh C. Paliwal | 1,000 |
| Theodore R. Samuels | 1,000 |
| Theodore R. Samuels | 1,000 |
| Theodore R. Samuels | 1,000 |
| James M. Cornelius | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Thomas J. Lynch | 1,000 |
| Sandra Leung | 1,000 |
| Joseph C. Caldarella | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Lamberto Andreotti | 1,000 |
| Louis S. Schmukler | 1,000 |
| Joseph C. Caldarella | 1,000 |
| Louis S. Schmukler | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 72 | 72 | 72 | 72 |
| Low Target Price Estimate | 47 | 47 | 47 | 47 |
| Mean Target Price Estimate | 60.55 | 60.91 | 60.91 | 60.55 |
| Standard Deviation | 7.88 | 8.19 | 8.19 | 7.88 |
| Date of Most Recent Estimate | 06/05/18 | 05/23/18 | 05/14/18 | 06/11/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 11-K | An annual report of employee stock purchase savings and similar plans | 16 | 2018-05-22 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-08 |
| 8-K | Report of unscheduled material events or corporate changes. | 3 | 2018-05-03 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-02 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 45 | 2018-04-26 |
| 8-K | Report of unscheduled material events or corporate changes. | 27 | 2018-04-26 |
| DEFA14A | Additional proxy soliciting materials - definitive | 15 | 2018-04-23 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-04-05 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 7 |
| Moderate Buy | 0 | 0 | 1 | 1 |
| Hold | 8 | 7 | 6 | 6 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 1 | 1 |
| Mean Rec. | 2.23 | 2.08 | 2.18 | 2.1 |
© 2021 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
Gathering Data... Please wait